8-K: Helius Medical Technologies Reports Q1 2024 Financial Results and Business Updates

Helius Medical Technologies announced its first quarter 2024 financial results, highlighted by increased revenue and progress towards Medicare reimbursement for its PoNS device.

Summary

• Helius Medical Technologies reported a revenue of $135 thousand for the first quarter of 2024, an increase from $111 thousand in the same period of 2023.
• The company's operating loss decreased to $3.4 million in Q1 2024, compared to $3.8 million in Q1 2023.
• Net loss for the quarter was $2.5 million, consistent with the net loss in the first quarter of 2023.
• The company's loss per share improved to $3.08 from $4.42 in the prior year's first quarter.
• Helius received preliminary Medicare payment determinations for the PoNS device, with final rates expected on October 1, 2024.
• The company raised $5.6 million in net proceeds through a public offering, extending its cash runway into 2025.
• Helius is on track for an early 2025 regulatory submission for stroke indication of the PoNS device.
• The company added six new sites to its stroke registrational program in the U.S. and Canada.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in reimbursement and regulatory pathways, but the company is still operating at a loss and reliant on external funding.

Positives

• Revenue increased year-over-year, indicating growing product sales in the U.S. and Canada.
• Operating loss decreased, suggesting improved cost management.
• The successful public offering provides additional capital to support operations and development.
• Preliminary Medicare payment determinations for the PoNS device are a significant step towards broader reimbursement.
• The company is on track for an early 2025 regulatory submission for stroke indication.
• The partnership with Lovell Government Services expands access to federal healthcare systems.

Negatives

• The company continues to operate at a loss, with a net loss of $2.5 million for the quarter.
• The cost of revenue remained relatively flat despite increased sales, indicating potential inefficiencies.
• The company is still reliant on external funding to maintain operations.

Risks

• The company's future cash position is dependent on securing additional funding.
• There are uncertainties associated with the development, commercialization, and success of the PoNS device.
• The company faces risks related to manufacturing, labor shortages, and supply chain disruptions.
• There is no guarantee of obtaining national Medicare insurance coverage or favorable reimbursement codes.
• The company's ability to build internal commercial infrastructure and secure state distribution licenses is not guaranteed.
• The regulatory submission and approval process for the PoNS device is subject to uncertainty.

Future Outlook

The company anticipates an early 2025 regulatory submission for stroke indication of the PoNS device and expects the establishment of Medicare payment rates to facilitate broader reimbursement and a pathway to positive cash flow.

Management Comments

• We marched one step closer to an important milestone when CMS released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece earlier this month.
• We believe the establishment of Medicare payment rates will make it easier to expand reimbursement across third-party payers, creating a pathway to positive cash flow as we continue pursuing stroke authorization in the U.S.
• Its an exciting time at Helius with the achievement of two monumental goals in sight and the cash that will help us get there.

Industry Context

This announcement reflects the ongoing efforts of neurotech companies to gain regulatory approvals and reimbursement for innovative medical devices. The focus on Medicare reimbursement is a common strategy for medical device companies to achieve commercial success.

Comparison to Industry Standards

• The revenue of $135 thousand is relatively low compared to established medical device companies, but is typical for a company in the early commercialization phase.
• The operating loss of $3.4 million is not unusual for a company investing heavily in research and development and commercialization.
• The successful capital raise of $5.6 million is a positive step, but the company will likely need further funding to achieve profitability.
• The progress towards Medicare reimbursement is a key milestone, as it is a major hurdle for medical device companies to achieve widespread adoption.
• Companies like NeuroMetrix and Second Sight Medical Products, which also focus on neuromodulation, have faced similar challenges in securing reimbursement and achieving profitability.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and progress towards commercialization.
• Employees will be impacted by the company's ability to secure funding and achieve its business objectives.
• Patients will benefit from the potential availability of the PoNS device for treating gait and balance deficits.
• The company's suppliers and contract manufacturers will be impacted by the company's production and sales volumes.

Next Steps

• The company will present arguments at the HCPCS public meeting to support higher reimbursement rates.
• The company will continue to advance its stroke registrational program.
• The company is targeting an early 2025 regulatory submission for stroke indication.

Key Dates

Keywords

PoNS, neuromodulation, Medicare, reimbursement, stroke, gait, balance, Helius Medical Technologies, regulatory submission, medical device